Full text is available at the source.
Abstract
Targeted anticancer therapies face challenges such as poor bioavailability and limited tumor penetration.
- Current targeted therapies include monoclonal antibodies, antibody-drug conjugates, siRNA, small-molecule inhibitors, and PROTACs.
- First-generation lipid-based nanoparticles (LBNPs) exploit the enhanced permeability and retention (EPR) effect but are insufficient alone due to tumor heterogeneity.
- The design of LBNPs must consider the structural complexities and biological barriers of each therapeutic modality.
- Optimizations for various nanocarriers involve customized lipid compositions, active targeting surface modifications, and the use of ionizable lipids to address endosomal entrapment.
- Optimal administration routes are linked to these structural designs, with formulation methods varying from traditional emulsification to advanced techniques like microfluidics.
- Clinical challenges for nanomedicines stem more from manufacturing and regulatory issues than from preclinical efficacy.
Simplified